( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们客服联系。| 中文名称: | BMS-795311 一键复制产品信息 | ||||
|---|---|---|---|---|---|
| 英文名称: | BMS-795311 | ||||
| 别名: | BMS-795311 N-[(1R)-1-(3-Cyclopropyloxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide | ||||
| CAS No: | 939390-99-5 | 分子式: | C33H23F10NO3 | 分子量: | 671.52 |
| CAS No: | 939390-99-5 | ||||
| 分子式: | C33H23F10NO3 | ||||
| 分子量: | 671.52 | ||||
基本信息
|
产品编号: |
B11363 |
||||
|
产品名称: |
BMS-795311 |
||||
|
CAS: |
939390-99-5 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
|
|
||||
|
分子式: |
溶于液体 |
|
|
||
|
分子量 |
671.52 |
|
|
||
|
化学名: |
N-[(1R)-1-(3-Cyclopropyloxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide |
||||
生物活性
|
产品描述 |
一种有效的,具有口服活性的胆固醇酯转移蛋白CETP抑制剂 |
|
|
靶点 |
IC50: 4nM (CETP) |
|
|
体外研究 |
BMS-795311 (10μM; 24 hours) does not increase aldosterone synthase (CYP11B2) mRNA at 10μM in H295R cells |
|
|
体内研究 |
BMS-795311 (1-3mg/kg; oral administration) inhibits plasma CE transfer activity in human CETP (hCETP)/apoB-100 dual transgenic (Tg) mice. BMS-795311 (3-10mg/kg; p.o. for 3 days) increases high density lipoprotein-cholesterol (HDL-C) content. BMS-795311 (8mg/kg, i.v.) has no effect on mean, systolic, or diastolic blood pressure, heart rate, or locomotor activity in rat telemetry studies. BMS-795311 exhibits reasonable oral bioavailability (mice 37%, rats 37%, monkeys 20%, dogs 5%) and Cmax (mice 5.3, rats 17, monkeys 1.7, dogs 0.43 ng/mL) following oral administration (mice 10, rats 10, monkeys 5, dogs 5mg/kg). BMS-795311 exhibits terminal elimination half-lives (mice 6, rats 7, monkeys >18, dogs 10 h) due to low plasma clearance (2.0, 0.9, 0.9, and 1.4 mL/min/kg respectively) combined with little volumes of distribution (0.8, 0.4, 0.9, and 0.6 L/kg respectively) following intravenous administration (mice 5, rats 1, monkeys 4, dogs 1mg/kg) |
|
|
Animal Model: |
hCETP/apoB-100 dual Tg mice |
|
|
Dosage: |
1, 3mg/kg |
|
|
Administration: |
Oral administration |
|
|
Result: |
Inhibited CETP activity at a dose of 1mg/kg at the 8 h time point. |
|
|
|
||
|
Animal Model: |
Moderately fat-fed hamsters |
|
|
Dosage: |
3, 10mg/kg |
|
|
Administration: |
Oral administration for 3 days |
|
|
Result: |
Increased plasma high density lipoprotein-cholesterol (HDL-C) content by 45% when dosed at 10mg/kg. |
|
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液,使用的计算公式为:
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为:C1V1 = C2V2 ( 输入 输出 )
母液,添加 300 μLPEG300
混匀澄清,再加 50μLTween80, 混匀澄清,再加 600μLSaline/PBS/ddH2O
混匀澄清方案所需的各种助溶剂如: DMSO , PEG300 / PEG400 , Tween 80 , SBE-β-CD , 玉米油 等, 均可点击跳转或在网站搜索购买。
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
.png)
